The Future Is Fluid
Liquid Biopsy Has Proven Its Mettle in the Fight against NSCLC and May Soon Also Be Standard of Care in Other Cancers
Genomics Brings Heavy Lifting to Immuno-Oncology
The Synergy of Two Burgeoning Fields Will Lead to Improved Precision Medicine
Singling Out RNA Biomarkers in Situ
ACD’s ISH Platform Achieves Single-Base Resolution and Retains Morphological Context
Microanalyte MDx Goes Mainstream
Nucleic Acid Analytes Are Reliable Sources of Data for Diagnostic Calculations
For full access to this article login to GEN Select now.
Cancer Diagnostics Leverage Decreasing Cost of Sequencing
Dx companies are investing heavily in computational and informatics platforms in order for genetic sequencing to be of value to clinicians.
Not registered yet? Please fill out the form below and enjoy complimentary access to this and an exclusive collection of premium content and personalization features as a GEN Select insider. Learn More.
Get GEN Select Access Now
- Do not put any letters or characters here if you are not a spy program.